February 2026 in “Pharmaceuticals” This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.
12 citations
,
September 2002 in “Epilepsia” This paper discusses the methods and challenges of postmarketing surveillance for new antiepileptic drugs, emphasizing the necessity of such data collection to identify adverse effects and assess drug effectiveness beyond initial trials.
November 2023 in “Frontiers in pharmacology” This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition.
1 citations
,
October 2025 in “International Journal of Dermatology” In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.
February 2023 in “European Journal of Medical Research” This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.
June 2026 in “British Journal of Dermatology” This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.
June 2026 in “Precision medicine and engineering.” In this study, researchers created a hydrogel that reduces oxidative stress and releases a pro-angiogenic drug in response to enzyme activity, which accelerated healing and improved tissue regeneration in chronic diabetic wounds during in vivo experiments.
May 2025 in “Frontiers in Immunology” This paper discusses the balance between target tissue destruction and recovery rates in autoimmune diseases, proposing that high recovery rates are crucial for remitting-relapsing patterns, while exercise might not be neuroprotective in secondary progressive multiple sclerosis.
8 citations
,
January 2013 in “European Journal of Dermatology” This article reviews the use of alitretinoin for corticosteroid-refractory chronic hand eczema and explores its potential therapeutic benefits in other skin conditions, but reports no clinical results.
April 2026 in “Diagnostics” This review outlines the use of quantitative imaging techniques in monitoring tendon response to platelet-rich plasma treatment for chronic tendinopathy and reports that these methods may aid in tailoring PRP protocols.
March 2026 in “Bioengineering & Translational Medicine” This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.
September 2025 in “Healthcare” This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.
33 citations
,
August 2018 in “Cochrane Database of Systematic Reviews” This review evaluates the efficacy and safety of enteral nutrition for maintaining remission in quiescent Crohn's disease but finds the evidence inconclusive and calls for further research.
This study found that a mesenchymal stromal cell-derived regenerative extracellular matrix (rECM) significantly accelerated wound closure and improved healing in diabetic mice, also enhancing nerve and blood vessel formation compared to controls.
21 citations
,
March 2002 in “Neurology” This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.
36 citations
,
July 2017 in “Journal of controlled release” In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.
September 2019 in “Journal of Investigative Dermatology” This study demonstrated that an RO formulation significantly improved neck wrinkles after 8 weeks of application, compared to a placebo, in Japanese female subjects.
January 2016 in “Georg Thieme Verlag eBooks” Understanding and careful application of dermabrasion and microdermabrasion can minimize risks and improve patient outcomes.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.
June 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This pilot study suggests that a new preparation of platelet-rich plasma gel may improve symptoms and tissue regeneration in patients with en coup de sabre scleroderma, though further trials are needed to clarify its role.
62 citations
,
July 2022 in “Science Immunology” This study discovered that TREM2 macrophages influenced by squalene play a role in acne's development by hindering the killing of Cutibacterium acnes, helping explain why benzoyl peroxide is effective in treatment.
12 citations
,
January 2019 in “Regenerative Medicine” In this commentary, the authors discuss the challenges and proposals for responsibly translating regenerative therapies into clinical practice, emphasizing the need for patient education, quality control, and real-world evidence to validate these therapies and address ongoing misinformation in the field.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.
January 2025 in “PROTEOMICS” This study discusses the rising interest in drug repositioning, particularly in response to COVID-19, and highlights various computational and experimental approaches used for repurposing existing drugs across different diseases, including rare conditions and chronic kidney disease.
July 2024 in “Journal of Investigative Dermatology” CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.
July 2023 in “Clinical, cosmetic and investigational dermatology” In this study, reflectance confocal microscopy was used to diagnose periorificial dermatitis, revealing specific skin changes such as hair follicle dilatation, increased vascular density, and inflammation, which help distinguish it from similar conditions.
8 citations
,
May 2022 in “International journal of nanomedicine” This study developed a fully natural resveratrol nanoparticle system using lecithin, showing potent anti-cancer activity in vitro and increased tumoral uptake in vivo on breast cancer models.
1 citations
,
June 2023 in “ScienceRise Pharmaceutical Science” This study explored a computer simulation method for selecting emulsion compositions in dermatology, finding that the PS biocomplex can be effectively used as an emulsifier or co-emulsifier, which streamlines the development process and reduces experimental demands.
53 citations
,
August 2014 in “Cochrane library” This review found no evidence supporting the efficacy of methotrexate for inducing remission in active ulcerative colitis compared to placebo or active comparators.
13 citations
,
April 2020 in “European Journal of Dermatology” This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.